Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients

被引：0
|
作者：
Eiji Shinto
Eiji Oki
Mototsugu Shimokawa
Shigeki Yamaguchi
Megumi Ishiguro
Seiji Hasegawa
Yasumasa Takii
Hideyuki Ishida
Tetsuya Kusumoto
Masaru Morita
Naohiro Tomita
Manabu Shiozawa
Masafumi Tanaka
Heita Ozawa
Yojiro Hashiguchi
Shinobu Ohnuma
Sachiyo Tada
Tomoko Matsushima
Keisuke Yamagishi
Kazuo Hase
机构：
[1] National Defense Medical College,Department of Surgery
[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[3] Yamaguchi University Graduate School of Medicine,Department of Biostatistics
[4] Tokyo Women’s Medical University,Department of Surgery, Division of Colorectal Surgery
[5] Tokyo Medical and Dental University,Medical Innovation Promotion Center
[6] Saiseikai Yokohamashi Nanbu Hospital,Department of Surgery
[7] Niigata Cancer Center Hospital,Department of Gastroenterological Surgery
[8] Saitama Medical Center,Department of Digestive Tract and General Surgery
[9] Saitama Medical University,Department of Gastroenterological Surgery, Clinical Research Center, Cancer Research Division
[10] National Hospital Organization Kyushu Medical Center,Department of Gastroenterological Surgery
[11] National Hospital Organization Kyushu Cancer Center,Cancer Treatment Center
[12] Toyonaka Municipal Hospital,Department of Gastrointestinal Surgery
[13] Kanagawa Cancer Center,Coloproctology Center
[14] Takano Hospital,Department of Colorectal Surgery
[15] Tochigi Cancer Center,Department of Surgery
[16] Teikyo University School of Medicine,Department of Surgery
[17] Tohoku University Hospital,LS Business
[18] Sysmex Corporation,undefined
来源：
Annals of Surgical Oncology | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5239 / 5247
页数：8
相关论文
共 50 条
  • [31] PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study
    Puccini, A.
    Ferrando, L.
    Mazzarella, L.
    Frige, G.
    Pessino, A.
    Pastorino, A.
    Martelli, V.
    Garuti, A.
    Ballestrero, A.
    Torri, V.
    Labianca, R.
    Fassan, M.
    Lonardi, S.
    Zoppoli, G.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S13 - S13
  • [32] Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and II Rectal Cancer Patients
    Reimers, Marlies S.
    Kuppen, Peter J. K.
    Lee, Mark
    Lopatin, Margarita
    Tezcan, Haluk
    Putter, Hein
    Clark-Langone, Kim
    Liefers, Gerrit Jan
    Shak, Steve
    van de Velde, Cornelis J. H.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11):
  • [33] Molecular profiles and clinical outcome of stage UICC II colon cancer patients
    Groene, Joern
    Lenze, Dido
    Jurinovic, Vindi
    Hummel, Manuela
    Seidel, Henrik
    Leder, Gabriele
    Beckmann, Georg
    Sommer, Anette
    Gruetzmann, Robert
    Pilarsky, Christian
    Mansmann, Ulrich
    Buhr, Heinz-Johannes
    Stein, Harald
    Hummel, Michael
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (07) : 847 - 858
  • [34] Molecular profiles and clinical outcome of stage UICC II colon cancer patients
    Jörn Gröne
    Dido Lenze
    Vindi Jurinovic
    Manuela Hummel
    Henrik Seidel
    Gabriele Leder
    Georg Beckmann
    Anette Sommer
    Robert Grützmann
    Christian Pilarsky
    Ulrich Mansmann
    Heinz-Johannes Buhr
    Harald Stein
    Michael Hummel
    International Journal of Colorectal Disease, 2011, 26 : 847 - 858
  • [35] ADDITIONAL VALIDATION OF A GENOMIC SIGNATURE (COLOPRINT) FOR THE RISK STRATIFICATION OF STAGE II COLON CANCER PATIENTS
    Tabernero, J.
    Salazar, R.
    Roepman, P.
    Glas, A.
    Santos, C.
    Friess, H.
    Ramos, F.
    Capella, G.
    Simon, I
    Rosenberg, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 17 - 17
  • [36] Can CEA be a Risk Factor for Recurrence in Stage II Colon Cancer?
    Suwa, Toshiyuki
    Sakurai, Joe
    Ohtsubo, Takehito
    TUMOR BIOLOGY, 2008, 29 : 83 - 83
  • [37] Impact of Adjuvant Chemotherapy on Recurrence Risk in Stage II Colon Cancer
    Adesoye, T.
    Hu, C.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S91 - S91
  • [38] Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer
    Belt, Eric J. Th
    Brosens, Rebecca P. M.
    Delis-van Diemen, Pien M.
    Bril, Herman
    Tijssen, Marianne
    van Essen, Dirk F.
    Heymans, Martijn W.
    Belien, Jeroen A. M.
    Stockmann, Hein B. A. C.
    Meijer, Sybren
    Meijer, Gerrit A.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S682 - S692
  • [39] Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer
    Eric J. Th. Belt
    Rebecca P. M. Brosens
    Pien M. Delis-van Diemen
    Herman Bril
    Marianne Tijssen
    Dirk F. van Essen
    Martijn W. Heymans
    Jeroen A. M. Beliën
    Hein B. A. C. Stockmann
    Sybren Meijer
    Gerrit A. Meijer
    Annals of Surgical Oncology, 2012, 19 : 682 - 692
  • [40] Recurrence risk analysis for stage II and III colorectal cancer, and the implications of diabetes mellitus as a risk factor for the recurrence of stage III colorectal cancer
    Kimura, Naoya
    Hiraki, Masatsugu
    Furukawa, Shunsuke
    Okuyama, Keiichiro
    Kohya, Naohiko
    Sakai, Masashi
    Kawaguchi, Atsushi
    Ikubo, Akashi
    Samejima, Ryuichiro
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 21 (06)
12345